Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
P/B ratio for Praxis Precision Medicines, Inc. (PRAX)
P/B ratio as of 2023: 2.11
According to Praxis Precision Medicines, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.11. At the end of 2022 the company had a P/B ratio of 1.44.
P/B ratio history for Praxis Precision Medicines, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.11 |
| 2022 | 1.44 |
| 2021 | 3.33 |
| 2020 | 1.71 |
| 2019 | 1.06 |
| 2018 | 2.46 |